Jove
Visualize
Contact Us

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

10.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.5K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.4K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.4K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

168
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
168
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.6K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.6K
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

332
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
332
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

224
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
224

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TRiC-assisted folding of class I HDAC family proteins regulated by distinct co-chaperone and cofactor networks.

Science advances·2026
Same author

Amino acid substitutions at the G118 hotspot in dihydroorotate dehydrogenase confer olorofim resistance in <i>Aspergillus flavus</i>.

Microbiology spectrum·2026
Same author

Altered Static and Dynamic Functional Motor Networks in Essential Tremor After Magnetic Resonance-Guided Focused Ultrasound: A Resting-State Functional MRI Study.

Academic radiology·2026
Same author

A chromosome-level genome assembly and annotation of the marbled rockfish (Sebastiscus marmoratus).

Scientific data·2026
Same author

Design and Synthesis of a Novel Covalent Dihydropteridinone Derivative as a Highly Potent and Orally Bioavailable PLK1 Inhibitor for the Treatment of Chronic Myeloid Leukemia.

Journal of medicinal chemistry·2026
Same author

SSR-Based Genetic Diversity, Population Structure, and Marker-Trait Associations for Popping-Related Traits in Popcorn Germplasm.

Genes·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Nov 23, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.0K

Graph-based generative models for de Novo drug design.

Xiaolin Xia1, Jianxing Hu1, Yanxing Wang1

  • 1State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Haidian District, 100191 Beijing, China.

Drug Discovery Today. Technologies
|January 2, 2021
PubMed
Summary

This review introduces graph-based deep generative neural networks for de novo drug design. These models generate novel drug candidates with desired properties, advancing pharmaceutical research.

More Related Videos

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

842
Curation of Computational Chemical Libraries Demonstrated with Alpha-Amino Acids
08:21

Curation of Computational Chemical Libraries Demonstrated with Alpha-Amino Acids

Published on: April 13, 2022

2.9K

Related Experiment Videos

Last Updated: Nov 23, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.0K
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

842
Curation of Computational Chemical Libraries Demonstrated with Alpha-Amino Acids
08:21

Curation of Computational Chemical Libraries Demonstrated with Alpha-Amino Acids

Published on: April 13, 2022

2.9K

Area of Science:

  • Medicinal Chemistry
  • Computational Chemistry
  • Artificial Intelligence in Drug Discovery

Background:

  • Drug discovery necessitates identifying novel chemical entities with optimal properties for pharmaceutical activity.
  • De novo drug design aims to create and refine new ligands for biological targets from the ground up.
  • Graph-based deep generative neural networks offer a promising computational approach to de novo drug design.

Purpose of the Study:

  • To review graph representation and graph-based generative models for de novo drug design.
  • To categorize and analyze four distinct architectures of these generative models.
  • To explore future directions for graph-based generative models in drug discovery.

Main Methods:

  • Introduction to graph representation in chemical space.
  • Summary and categorization of four main architectures of graph-based generative models.
  • Discussion of generative models applied to scaffold- and fragment-based design.

Main Results:

  • Characterization of the strengths and weaknesses of different graph-based generative model architectures.
  • Overview of current applications in scaffold- and fragment-based drug design.
  • Identification of key trends and future research avenues.

Conclusions:

  • Graph-based deep generative models represent a significant advancement in de novo drug design.
  • Understanding different model architectures is crucial for optimizing ligand generation.
  • Future research should focus on refining these models for more efficient and effective drug discovery pipelines.